Patents by Inventor Roderike Pohl
Roderike Pohl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170128542Abstract: Stabilized glucagon formulations are provided, in the form of a clear solution. The formulations include glucagon in a non-aqueous diluent and an antioxidant The diluent and antioxidant are selected to provide a glucagon formulation with increased stability when compared to glucagon without the anti-oxidant and/or the diluent and which shows a comparable onset of action and duration of glucose response. The compositions can be used to treat subjects with very low blood sugar (severe hypoglycemia) that can happen in subjects who have diabetes and use insulin.Type: ApplicationFiled: November 9, 2016Publication date: May 11, 2017Inventors: Ming Li, Roderike Pohl, Robert Feldstein, Robert Hauser, Errol De Souza
-
Patent number: 9610329Abstract: A formulation composed of a sugar such as glucose and a surfactant such as myristoyl lysophosphocholine (LMPC) has been designed to stabilize both hydrophilic and hydrophobic portions of the glucagon molecule, under prolonged physiological conditions, in a formulation that is sufficiently similar to the pH and osmolarity of plasma so as not to induce or to minimize site irritation. The combination of a simple sugar and an surfactant stabilizes the glucagon molecule in an aqueous solution for seven days at 37° C.Type: GrantFiled: September 27, 2010Date of Patent: April 4, 2017Assignee: Albireo Pharma, Inc.Inventors: Solomon S. Steiner, Robert Hauser, Ming Li, Robert Feldstein, Roderike Pohl
-
Patent number: 9399065Abstract: Compositions and methods for modulating injection site pain associated with rapid acting injectable insulin formulations have been developed for subcutaneous injection. The formulations contain insulin in combination with a zinc chelator such as ethylenediaminetetraacetic acid (“EDTA”), a dissolution/stabilization agent such as citric acid, a magnesium salt, and, optionally, additional excipients. New presentations include rapid acting concentrated insulin formulations and a way to enhance the absorption of commercially available rapid acting analog formulations by mixing them with a vial containing dry powder excipients that accelerate their absorption. Devices for mixing excipient and insulin together at the time of administration, while minimizing residence time of the mixture, are also described.Type: GrantFiled: May 12, 2014Date of Patent: July 26, 2016Assignee: Biodel Inc.Inventors: Roderike Pohl, Robert Hauser, Errol De Souza, Ming Li, Bryan R. Wilson
-
Patent number: 9381247Abstract: Compositions and methods for modulating injection site pain associated with rapid acting injectable insulin formulations have been developed for subcutaneous injection. The formulations contain insulin in combination with a zinc chelator such as ethylenediaminetetraacetic acid (“EDTA”), a dissolution/stabilization agent such as citric acid, a magnesium salt, and, optionally, additional excipients. New presentations include rapid acting concentrated insulin formulations and a way to enhance the absorption of commercially available rapid acting analog formulations by mixing them with a vial containing dry powder excipients that accelerate their absorption. Devices for mixing excipient and insulin together at the time of administration, while minimizing residence time of the mixture, are also described.Type: GrantFiled: March 14, 2013Date of Patent: July 5, 2016Assignee: Biodel Inc.Inventors: Roderike Pohl, Robert Hauser, Ming Li, Bryan R. Wilson
-
Publication number: 20150273022Abstract: Compositions and methods for enhancing the stability of rapid acting injectable insulin formulations have been developed for subcutaneous injection. The formulations contain insulin in combination with a zinc chelator such as ethylenediaminetetraacetic acid (“EDTA”), a dissolution/stabilization agent such as citric acid, a magnesium salt, a zinc compound and, optionally, additional excipients. New presentations include rapid acting concentrated insulin formulations and a way to enhance the absorption of commercially available rapid acting analog formulations while maintaining insulin stability.Type: ApplicationFiled: February 10, 2015Publication date: October 1, 2015Inventors: Bryan R. Wilson, Pragati Ravula, Ming Li, Roderike Pohl, Robert Hauser
-
Patent number: 9060927Abstract: Injectable insulin formulations with improved stability and rapid onset of action are described herein. The formulations may be for subcutaneous, intradermal or intramuscular administration. In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a chelator and dissolution agent, and optionally additional excipients. In the preferred embodiment, the formulation contains human insulin, a zinc chelator such as EDTA and a dissolution agent such as citric acid or sodium citrate. These formulations are rapidly absorbed into the blood stream when administered by subcutaneous injection. In the preferred embodiment, the insulin is provided as a clear liquid, neutral pH, in a multi-use sterile vial. In an alternative embodiment, the insulin is provided as a powder in a sterile vial.Type: GrantFiled: March 3, 2009Date of Patent: June 23, 2015Assignee: Biodel Inc.Inventors: Solomon S. Steiner, Roderike Pohl, Ming Li, Robert Hauser
-
Publication number: 20150122258Abstract: A dry powder inhaler having improved aerodynamic properties for diluting, dispersing, and metering drug particles for increasing the efficiency of pulmonary drug delivery to a patient is described. The inhaler comprises, in general, a housing having an air intake, an airflow-control/check-valve, a mixing section and a mouthpiece. A cartridge loaded with a single dose of medicament can be installed in the mixing section.Type: ApplicationFiled: January 8, 2015Publication date: May 7, 2015Inventors: Solomon S. Steiner, Trent A. Poole, Per B. Fog, Roderike Pohl, Michael Crick, Robert Feldstein
-
Patent number: 8950397Abstract: A dry powder inhaler having improved aerodynamic properties for diluting, dispersing, and metering drug particles for increasing the efficiency of pulmonary drug delivery to a patient is described. The inhaler comprises, in general, a housing having an air intake, an air flow-control/check-valve, a mixing section and a mouthpiece. A cartridge loaded with a single dose of medicament can be installed in the mixing section.Type: GrantFiled: June 6, 2012Date of Patent: February 10, 2015Assignee: MannKind CorporationInventors: Solomon S. Steiner, Trent A. Poole, Per B. Fog, Roderike Pohl, Michael Crick, Robert Feldstein
-
Patent number: 8933023Abstract: Injectable insulin formulations with improved stability and rapid onset of action are described herein. The formulations may be for subcutaneous, intradermal or intramuscular administration. In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a chelator and dissolution agent, and optionally additional excipients. In the preferred embodiment, the formulation contains human insulin, a zinc chelator such as EDTA and a dissolution agent such as citric acid. These formulations are rapidly absorbed into the blood stream when administered by subcutaneous injection. In the preferred embodiment, the insulin is provided as a dry powder in a sterile vial. This is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water, a zinc chelator such as EDTA and a dissolution agent such as citric acid shortly before or at the time of administration.Type: GrantFiled: January 15, 2014Date of Patent: January 13, 2015Assignee: Biodel Inc.Inventors: Roderike Pohl, Solomon S. Steiner
-
Publication number: 20140357554Abstract: Compositions and methods for modulating injection site pain associated with rapid acting injectable insulin formulations have been developed for subcutaneous injection. The formulations contain insulin in combination with a zinc chelator such as ethylenediaminetetraacetic acid (“EDTA”), a dissolution/stabilization agent such as citric acid, a magnesium salt, and, optionally, additional excipients. New presentations include rapid acting concentrated insulin formulations and a way to enhance the absorption of commercially available rapid acting analog formulations by mixing them with a vial containing dry powder excipients that accelerate their absorption. Devices for mixing excipient and insulin together at the time of administration, while minimizing residence time of the mixture, are also described.Type: ApplicationFiled: May 12, 2014Publication date: December 4, 2014Inventors: Roderike Pohl, Robert Hauser, Errol De Souza, Ming Li, Bryan R. Wilson
-
Publication number: 20140135263Abstract: Injectable insulin formulations with improved stability and rapid onset of action are described herein. The formulations may be for subcutaneous, intradermal or intramuscular administration. In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a chelator and dissolution agent, and optionally additional excipients. In the preferred embodiment, the formulation contains human insulin, a zinc chelator such as EDTA and a dissolution agent such as citric acid. These formulations are rapidly absorbed into the blood stream when administered by subcutaneous injection. In the preferred embodiment, the insulin is provided as a dry powder in a sterile vial. This is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water, a zinc chelator such as EDTA and a dissolution agent such as citric acid shortly before or at the time of administration.Type: ApplicationFiled: January 15, 2014Publication date: May 15, 2014Applicant: Biodel Inc.Inventors: Roderike Pohl, Solomon S. Steiner
-
Patent number: 8637458Abstract: A basal insulin formulation composed of insulin, preferably insulin glargine, injectable zinc and injectable iron compounds as precipitating and/or stabilizing agents has been developed for subcutaneous, intradermal or intramuscular administration. The formulation is designed to form a precipitate of insulin following injection, creating a slow releasing “basal insulin” over a period of 12 to 24 hours.Type: GrantFiled: May 12, 2010Date of Patent: January 28, 2014Assignee: Biodel Inc.Inventors: Roderike Pohl, Nandini Kashyap, Robert Hauser, Koray Ozhan, Solomon S. Steiner
-
Publication number: 20120240929Abstract: A dry powder inhaler having improved aerodynamic properties for diluting, dispersing, and metering drug particles for increasing the efficiency of pulmonary drug delivery to a patient is described. The inhaler comprises, in general, a housing having an air intake, an air flow-control/check-valve, a mixing section and a mouthpiece. A cartridge loaded with a single dose of medicament can be installed in the mixing section.Type: ApplicationFiled: June 6, 2012Publication date: September 27, 2012Applicant: MANNKIND CORPORATIONInventors: Solomon S. Steiner, Trent A. Poole, Per B. Fog, Roderike Pohl, Michael Crick, Robert Feldstein
-
Publication number: 20120178675Abstract: Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of rapid acting injectable insulin formulations are described herein. In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a zinc chelator such as ethylenediaminetetraacetic acid (“EDTA”) and a dissolution/stabilization agent, and optionally additional excipients. Calcium disodium EDTA is less likely to remove calcium from the body, and typically has less pain on injection in the subcutaneous tissue. Modulating the type and quantity of EDTA can change the insulin absorption profile. Increasing the quantity of citrate can further enhance absorption and chemically stabilize the formulation. In the preferred embodiment, the formulation contains human insulin, calcium disodium EDTA and a dissolution/stabilization agent such as citric acid or sodium citrate.Type: ApplicationFiled: July 5, 2011Publication date: July 12, 2012Inventors: Roderike Pohl, Solomon Steiner, Robert Hauser, Richard Seibert, Ming Li
-
Patent number: 8215300Abstract: A dry powder inhaler having improved aerodynamic properties for diluting, dispersing, and metering drug particles for increasing the efficiency of pulmonary drug delivery to a patient is described. The inhaler comprises, in general, a housing having an air intake, an air flow-control/check-valve, a mixing section and a mouthpiece. A cartridge loaded with a single dose of medicament can be installed in the mixing section.Type: GrantFiled: April 14, 2008Date of Patent: July 10, 2012Assignee: MannKind CorporationInventors: Solomon S. Steiner, Trent A. Poole, Per B. Fog, Roderike Pohl, Michael Crick, Robert Feldstein
-
Patent number: 8084420Abstract: An injectable formulation containing a rapid acting insulin and a long acting insulin has been developed. The pH of the rapid acting insulin is adjusted so that the long acting insulin, remains soluble when they are mixed together. Preferably, the formulation is administered before breakfast, provides adequate bolus insulin levels to cover the meal and basal insulin for up to 24 hours, and does not produce hypoglycemia after the meal. Lunch and dinner can be covered by two bolus injections of a fast, rapid, or very rapid acting insulin. Alternatively, by adjusting the ratio of rapid to long acting insulin, the long acting insulin may be shortened to a 12 hour formulation, and re-administered to the patient at dinner time, providing a safe and effective basal insulin level until morning. As a result, a patient using intensive insulin therapy should only inject three times a day.Type: GrantFiled: November 26, 2008Date of Patent: December 27, 2011Assignee: Biodel Inc.Inventors: Solomon S. Steiner, Roderike Pohl
-
Publication number: 20110281790Abstract: A basal insulin formulation composed of insulin, preferably insulin glargine, injectable zinc and injectable iron compounds as precipitating and/or stabilizing agents has been developed for subcutaneous, intradermal or intramuscular administration. The formulation is designed to form a precipitate of insulin following injection, creating a slow releasing “basal insulin” over a period of 12 to 24 hours.Type: ApplicationFiled: May 12, 2010Publication date: November 17, 2011Inventors: Roderike Pohl, Nandini Kashyap, Robert Hauser, Koray Ozhan, Solomon S. Steiner
-
Publication number: 20110237510Abstract: A formulation composed of a sugar such as glucose and a surfactant such as myristoyl lysophosphocholine (LMPC) has been designed to stabilize both hydrophilic and hydrophobic portions of the glucagon molecule, under prolonged physiological conditions, in a formulation that is sufficiently similar to the pH and osmolarity of plasma so as not to induce or to minimize site irritation. The combination of a simple sugar and an surfactant stabilizes the glucagon molecule in an aqueous solution for seven days at 37° C.Type: ApplicationFiled: September 27, 2010Publication date: September 29, 2011Inventors: Solomon S. Steiner, Robert Hauser, Ming Li, Robert Feldstein, Roderike Pohl
-
Publication number: 20110097386Abstract: A formulation composed of a sugar such as glucose and a surfactant such as myristoyl lysophosphocholine (LMPC) has been designed to stabilize both hydrophilic and hydrophobic portions of the glucagon molecule, under prolonged physiological conditions, in a formulation that is sufficiently similar to the pH and osmolarity of plasma so as not to induce or to minimize site irritation. The combination of a simple sugar and an surfactant stabilizes the glucagon molecule in an aqueous solution for seven days at 37° C.Type: ApplicationFiled: March 1, 2010Publication date: April 28, 2011Inventors: Solomon S. Steiner, Robert Hauser, Ming Li, Robert Feldstein, Roderike Pohl
-
Publication number: 20100227795Abstract: Injectable insulin formulations with improved stability and rapid onset of action are described herein. The formulations may be for subcutaneous, intradermal or intramuscular administration. In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a chelator and dissolution agent, and optionally additional excipients. In the preferred embodiment, the formulation contains human insulin, a zinc chelator such as EDTA and a dissolution agent such as citric acid or sodium citrate. These formulations are rapidly absorbed into the blood stream when administered by subcutaneous injection. In the preferred embodiment, the insulin is provided as a clear liquid, neutral pH, in a multi-use sterile vial. In an alternative embodiment, the insulin is provided as a powder in a sterile vial.Type: ApplicationFiled: March 3, 2009Publication date: September 9, 2010Inventors: Solomon S. Steiner, Roderike Pohl, Ming Li, Robert Hauser